

Ariel Graff-Guerrero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2060417/publications.pdf>

Version: 2024-02-01

183
papers

6,566
citations

66336

42
h-index

79691

73
g-index

186
all docs

186
docs citations

186
times ranked

7997
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigation of accelerated epigenetic aging in individuals suffering from schizophrenia in the context of lifetime suicide attempt. <i>Schizophrenia Research</i> , 2022, 243, 222-224.	2.0	3
2	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2022, 27, 744-757.	7.9	60
3	A measure of subjective substance use disorder awareness “ Substance Use Awareness and Insight Scale (SAS). <i>Drug and Alcohol Dependence</i> , 2022, 231, 109129.	3.2	3
4	Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 1205-1213.	6.1	13
5	Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110473.	4.8	13
6	Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E1-E10.	2.4	12
7	MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3341-3350.	2.4	2
8	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 113-115.	2.0	1
9	The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans. <i>European Neuropsychopharmacology</i> , 2022, 57, 39-49.	0.7	2
10	Childhood trauma exposure and personality traits in schizophrenia patients. <i>Schizophrenia Research</i> , 2022, 241, 221-227.	2.0	1
11	Tracking the Temporal Footprint Effect of Thermo Nociception and Denervation on the Brain’s Pain Matrix: fMRI and BOLD Study in Rats. <i>Journal of Pain Research</i> , 2022, Volume 15, 857-865.	2.0	0
12	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	7.9	44
13	Differential Methylation Analysis of Suicidal Ideation Severity in Schizophrenia with the Illumina MethylationEPIC Array. <i>Healthcare (Switzerland)</i> , 2022, 10, 809.	2.0	0
14	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210965.	2.7	17
15	Graph theory analysis of the dopamine D2 receptor network in Parkinson’s disease patients with cognitive decline. <i>Journal of Neuroscience Research</i> , 2021, 99, 947-965.	2.9	6
16	Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 319-332.	1.2	12
17	Lower striatal dopamine D2/3 receptor availability in obsessive-compulsive disorder: A meta-analysis of [11C]-raclopride and [123I]-IBZM studies. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2021, 28, 100618.	1.5	1
18	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab006.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Propiedades psicométricas de la Escala de Gaudibilidad (Moduladores de Disfrute) para Niños y Adolescentes (EGNA).. Anales De Psicología, 2021, 37, 69-76.	0.7	1
20	Measuring amphetamine-induced dopamine release in humans: A comparative meta-analysis of [¹¹ C]-raclopride and [¹¹ C]-(+)-PHNO studies. Synapse, 2021, 75, e22195.	1.2	9
21	Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. Journal of Psychiatric Research, 2021, 136, 468-473.	3.1	4
22	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. NPJ Schizophrenia, 2021, 7, 22.	3.6	35
23	Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Translational Psychiatry, 2021, 11, 219.	4.8	14
24	Measuring Amphetamine-Induced Dopamine Release in Humans: A Comparative Meta-Analysis of [¹¹ C]-Raclopride and [¹¹ C]-(+)-PHNO Studies. Biological Psychiatry, 2021, 89, S94-S95.	1.3	1
25	Cortical Thickness in Patients With Schizophrenia With Impaired Insight Into Illness. Biological Psychiatry, 2021, 89, S181-S182.	1.3	0
26	Linking Clozapine/Norclozapine Ratio with Glial Marker in Patients With Treatment Resistant Schizophrenia. Biological Psychiatry, 2021, 89, S252.	1.3	0
27	GWAS Analysis of Insight in Schizophrenia. Biological Psychiatry, 2021, 89, S136-S137.	1.3	0
28	Differences in Cortical Thickness Associated With Apathy in Cognitively Impaired Persons. Biological Psychiatry, 2021, 89, S273-S274.	1.3	0
29	Increased Regional Cerebral Blood Flow in the Parietal Regions in Patients With Schizophrenia With Impaired Insight. Biological Psychiatry, 2021, 89, S263-S264.	1.3	0
30	Theta Phase-Gamma Amplitude Coupling During Working Memory and its Relationships With Demographic, Clinical, Genetic, Neurochemical, and Neurostructural Measures in Older Adults at Risk for Dementia. Biological Psychiatry, 2021, 89, S350-S351.	1.3	0
31	Neuromelanin Accumulation in Patients With Schizophrenia: A Systematic Review and Meta-Analysis. Biological Psychiatry, 2021, 89, S253.	1.3	1
32	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. JAMA Psychiatry, 2021, 78, 667.	11.0	72
33	A Measure to Assess Illness Awareness in Problem Gambling: Gambling Awareness and Insight Scale (GAS). Journal of Gambling Studies, 2021, , 1.	1.6	4
34	Adiposity in schizophrenia: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 2021, 144, 524-536.	4.5	19
35	A measure of illness awareness in alcohol use disorder—Alcohol Use Awareness and Insight Scale (AAS). Drug and Alcohol Dependence, 2021, 226, 108813.	3.2	4
36	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. NeuroImage: Clinical, 2021, 32, 102852.	2.7	9

#	ARTICLE	IF	CITATIONS
37	Vaccine Hesitancy Is a Barrier to Achieving Equitable Herd Immunity Among Racial Minorities. <i>Frontiers in Medicine</i> , 2021, 8, 668299.	2.6	20
38	Anti-vaccination attitudes are associated with less analytical and more intuitive reasoning. <i>Psychology, Health and Medicine</i> , 2021, , 1-13.	2.4	3
39	Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. <i>Neuropharmacology</i> , 2020, 168, 107634.	4.1	48
40	Brain insulin action in schizophrenia: Something borrowed and something new. <i>Neuropharmacology</i> , 2020, 163, 107633.	4.1	31
41	Brain insulin action: Implications for the treatment of schizophrenia. <i>Neuropharmacology</i> , 2020, 168, 107655.	4.1	19
42	What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. <i>Neuropharmacology</i> , 2020, 163, 107591.	4.1	16
43	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 11-22.	3.2	34
44	Further in vivo characterization of [¹¹ C]â€(+)â€PHNO uptake into a retinaâ€like region of interest in humans. <i>Synapse</i> , 2020, 74, e22135.	1.2	1
45	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuropsychopharmacology</i> , 2020, 45, 632-640.	5.4	50
46	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109839.	4.8	16
47	Impaired Awareness of Problem and Pathological Gambling: A Review. <i>Journal of Gambling Studies</i> , 2020, 36, 39-50.	1.6	5
48	M23. ALTERATION OF REGIONAL CEREBRAL BLOOD FLOW MEASURED BY ARTERIAL SPIN LABELING IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S142-S142.	4.3	0
49	M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S166-S166.	4.3	0
50	M157. A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE. <i>Schizophrenia Bulletin</i> , 2020, 46, S195-S196.	4.3	0
51	Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 223, 279-288.	2.0	5
52	T212. LEVELS OF GLUTAMATERGIC NEUROMETABOLITES IN PATIENTS WITH SEVERE TREATMENT-RESISTANT SCHIZOPHRENIA: A PROTON MAGNETIC RESONANCE SPECTROSCOPY STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S313-S313.	4.3	0
53	Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review. <i>Nutrients</i> , 2020, 12, 3883.	4.1	15
54	Dorsolateral prefrontal cortex metabolites and their relationship with plasticity in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045879.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Theta-γ coupling and ApoE genotype in patients at risk for Alzheimer's dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e047573.	0.8	2
56	Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 138-149.	2.3	5
57	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. <i>Journal of Psychiatric Research</i> , 2020, 124, 151-158.	3.1	31
58	Design and Rationale of the PACT-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 733-751.	2.6	27
59	Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study. <i>Biological Psychiatry</i> , 2020, 87, S414.	1.3	0
60	DAS: The Diabetes Awareness and Insight Scale. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 189-194.	3.6	7
61	White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 100, 109871.	4.8	21
62	Improving Insight in Non-Treatment-Resistant Patients With Schizophrenia With Transcranial Direct Current Stimulation. <i>Biological Psychiatry</i> , 2020, 87, S186.	1.3	0
63	Brain degeneration in Parkinson's disease patients with cognitive decline: a coordinate-based meta-analysis. <i>Brain Imaging and Behavior</i> , 2019, 13, 1021-1034.	2.1	33
64	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. <i>European Psychiatry</i> , 2019, 61, 63-71.	0.2	12
65	Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2019, 211, 10-20.	2.0	15
66	Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. <i>Journal of Neuroimaging</i> , 2019, 29, 721-729.	2.0	6
67	T199. Assessing Neurometabolite Alterations in the Anterior Cingulate Cortex of Patients With Schizophrenia: A Multi-Site Proton Magnetic Resonance Spectroscopy Initiative. <i>Biological Psychiatry</i> , 2019, 85, S207.	1.3	0
68	S43. Structural Brain Differences Between Cognitively Impaired Patients With and Without Apathy. <i>Biological Psychiatry</i> , 2019, 85, S313.	1.3	0
69	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 208, 420-429.	2.0	32
70	Acute and long-term effects of electroconvulsive therapy on human dentate gyrus. <i>Neuropsychopharmacology</i> , 2019, 44, 1805-1811.	5.4	48
71	F182. Improving Insight into Psychosis With Transcranial Direct Current Stimulation in Schizophrenia. <i>Biological Psychiatry</i> , 2019, 85, S284.	1.3	0
72	S46. A Systematic Review of Case-Control Human Studies of Lead (Pb) in Alzheimer's Dementia. <i>Biological Psychiatry</i> , 2019, 85, S314.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2019, 33, 1199-1214.	4.0	47
74	Impaired illness awareness in schizophrenia and posterior corpus callosal white matter tract integrity. <i>NPJ Schizophrenia</i> , 2019, 5, 8.	3.6	11
75	Lead (Pb) in Alzheimer's Dementia: A Systematic Review of Human Case- Control Studies. <i>Current Alzheimer Research</i> , 2019, 16, 353-361.	1.4	9
76	Subiculum volumes associated with memory function in the oldest-old individuals aged 95+ years and older. <i>Geriatrics and Gerontology International</i> , 2019, 19, 347-351.	1.5	5
77	S167. Increased N-Acetylaspartate and Myo-Inositol Levels in Clozapine-Responders and Clozapine-Resistant Patients With Schizophrenia. <i>Biological Psychiatry</i> , 2019, 85, S361-S362.	1.3	0
78	S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study. <i>Biological Psychiatry</i> , 2019, 85, S368-S369.	1.3	0
79	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 207-213.	4.8	5
80	A meta-analysis of transcranial direct current stimulation for schizophrenia: 'Is more better?' <i>Journal of Psychiatric Research</i> , 2019, 110, 117-126.	3.1	40
81	Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2019, 24, 952-964.	7.9	225
82	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, 596-605.	1.3	94
83	Neuroimaging correlates of narcolepsy with cataplexy: A systematic review. <i>Neuroscience Research</i> , 2019, 142, 16-29.	1.9	22
84	Can we accurately classify schizophrenia patients from healthy controls using magnetic resonance imaging and machine learning? A multi-method and multi-dataset study. <i>Schizophrenia Research</i> , 2019, 214, 3-10.	2.0	53
85	Psychiatric benefits of lithium in water supplies may be due to protection from the neurotoxicity of lead exposure. <i>Medical Hypotheses</i> , 2018, 115, 94-102.	1.5	23
86	Reward motivation in humans and its relationship to dopamine D2/3 receptor availability: A pilot study with dual [11C]-raclopride and [11C]-(+)-PHNO imaging. <i>Journal of Psychopharmacology</i> , 2018, 32, 357-366.	4.0	10
87	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. <i>Psychiatry Research - Neuroimaging</i> , 2018, 273, 16-24.	1.8	14
88	Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. <i>Journal of Psychopharmacology</i> , 2018, 32, 509-523.	4.0	79
89	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , 2018, 28, 285-296.	0.7	6
90	Effect of electroconvulsive therapy on hippocampal and amygdala volumes: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2018, 212, 19-26.	2.8	94

#	ARTICLE	IF	CITATIONS
91	Kynurenine pathway in depression: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 90, 16-25.	6.1	199
92	Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 340-352.	4.8	49
93	The neural correlates of apathy in schizophrenia: An exploratory investigation. <i>Neuropsychologia</i> , 2018, 118, 34-39.	1.6	9
94	Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients. <i>Biological Psychiatry</i> , 2018, 83, 475-483.	1.3	66
95	Cross-cultural psychometric assessment of the VAGUS insight into psychosis scale – Spanish version. <i>Psychiatry Research</i> , 2018, 259, 450-454.	3.3	2
96	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 523-530.	2.7	11
97	F40201: ALGORITHMIC APPROACH TO THE MANAGEMENT OF AGITATION AND AGGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1383.	0.8	0
98	Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. <i>PLoS ONE</i> , 2018, 13, e0209584.	2.5	7
99	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 622.	2.6	115
100	F230. Glutamatergic Neurometabolite Levels in Patients With Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton MRS Study. <i>Biological Psychiatry</i> , 2018, 83, S328.	1.3	2
101	Does Family History of Alcohol Use Disorder Relate to Differences in Regional Brain Volumes? A Descriptive Review with New Data. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2369-2384.	2.4	5
102	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , 2018, 268, 114-122.	3.3	62
103	Reprint of OASIS – Obesity Awareness and Insight Scale. <i>Primary Care Diabetes</i> , 2018, 12, 371-378.	1.8	2
104	F6. Is it Possible to Elicit Progressive Functioning Decline Without Having Beta-Amyloid Pathology? Clinical Trajectories of Mild Cognitive Impairment With Suspected Non-Alzheimer's Pathology. <i>Biological Psychiatry</i> , 2018, 83, S239.	1.3	0
105	Structural and functional alterations of the suicidal brain: An updated review of neuroimaging studies. <i>Psychiatry Research - Neuroimaging</i> , 2018, 278, 77-91.	1.8	80
106	Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. <i>Experimental Eye Research</i> , 2018, 175, 32-41.	2.6	16
107	Exploring the relationship between social attachment and dopamine D _{2/3} receptor availability in the brains of healthy humans using [¹¹ C]-(+)-PHNO. <i>Social Neuroscience</i> , 2017, 12, 163-173.	1.3	12
108	Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit – Posterior parietal hemispheric imbalance. <i>Medical Hypotheses</i> , 2017, 100, 19-22.	1.5	1

#	ARTICLE	IF	CITATIONS
109	Vestibular stimulation improves insight into illness in schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2017, 251, 333-341.	3.3	6
110	Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood-brain barrier integrity?. <i>Brain</i> , 2017, 140, 865-867.	7.6	2
111	Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. <i>Psychoneuroendocrinology</i> , 2017, 81, 80-87.	2.7	10
112	Altered functional connectivity in brain networks underlying self-referential processing in delusions of reference in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2017, 263, 32-43.	1.8	31
113	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
114	Trait impulsiveness is related to smaller post-commissural putamen volumes in males but not females. <i>European Journal of Neuroscience</i> , 2017, 46, 2253-2264.	2.6	10
115	The relationship between subcortical brain volume and striatal dopamine D _{2/3} receptor availability in healthy humans assessed with [¹¹ C]-raclopride and [¹¹ C]-PHNO PET. <i>Human Brain Mapping</i> , 2017, 38, 5519-5534.	3.6	12
116	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 747-762.	2.6	9
117	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1-10.	1.2	18
118	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 341-347.	2.6	4
119	The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1766.	4.1	26
120	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 615-633.	2.6	23
121	Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans. <i>European Neuropsychopharmacology</i> , 2016, 26, 644-652.	0.7	23
122	Benzodiazepine Use Attenuates Cortical β -Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1028-1039.	1.2	19
123	β -Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 923-939.	1.2	15
124	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. <i>Psychopharmacology</i> , 2016, 233, 3803-3813.	3.1	11
125	Amyloid deposition in semantic dementia: a positron emission tomography study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1064-1074.	2.7	9
126	Estimating the effect of endogenous dopamine on baseline [¹¹ C]-PHNO binding in the human brain. <i>Synapse</i> , 2016, 70, 453-460.	1.2	12

#	ARTICLE	IF	CITATIONS
127	Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naïve Patients with First-Episode Psychosis: Implications for Excitotoxicity. <i>Neuropsychopharmacology</i> , 2016, 41, 2606-2613.	5.4	48
128	Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv105.	2.1	66
129	Cortical Amyloid β^2 Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 149-159.	2.3	38
130	Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naïve Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. <i>Schizophrenia Bulletin</i> , 2016, 42, 415-424.	4.3	80
131	The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 49-53.	4.8	17
132	Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2016, 41, 529-537.	5.4	24
133	Threshold of Dopamine D _{2/3} Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1557-e1563.	2.2	11
134	Lack of Age-Dependent Decrease in Dopamine D3 Receptor Availability: A [11C]-(+)-PHNO and [11C]-Raclopride Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1812-1818.	4.3	26
135	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 743-754.	2.6	33
136	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv014-pyv014.	2.1	59
137	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 351-356.	2.0	32
138	Lifetime History of Depression Predicts Increased Amyloid- β^2 Accumulation in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 907-919.	2.6	49
139	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	2.0	22
140	Abnormal white matter integrity in antipsychotic-naïve first-episode psychosis patients assessed by a DTI principal component analysis. <i>Schizophrenia Research</i> , 2015, 162, 14-21.	2.0	30
141	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia—A [11C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	2.0	17
142	Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: A pilot study. <i>Clinica Chimica Acta</i> , 2015, 449, 60-62.	1.1	29
143	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 927.	11.0	77
144	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2015, 164, 164-175.	2.0	75

#	ARTICLE	IF	CITATIONS
145	Non-Pharmacological Management for Patients with Frontotemporal Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 283-293.	2.6	26
146	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. <i>Medical Hypotheses</i> , 2015, 85, 391-396.	1.5	11
147	Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. <i>Schizophrenia Bulletin</i> , 2015, 42, sbv106.	4.3	16
148	Ventral Striatum Binding of a Dopamine D2/3 Receptor Agonist But Not Antagonist Predicts Normal Body Mass Index. <i>Biological Psychiatry</i> , 2015, 77, 196-202.	1.3	53
149	Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation. <i>Schizophrenia Bulletin</i> , 2015, 41, 44-56.	4.3	69
150	Estimating Endogenous Dopamine Levels at D2 and D3 Receptors in Humans using the Agonist Radiotracer [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 2769-2776.	5.4	31
151	The effects of aging on insight into illness in schizophrenia: a review. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 1145-1161.	2.7	58
152	Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: Resting state functional connectivity. <i>Schizophrenia Research</i> , 2014, 160, 43-50.	2.0	58
153	The VAGUS insight into psychosis scale – Self-report and clinician-rated versions. <i>Psychiatry Research</i> , 2014, 220, 1084-1089.	3.3	41
154	Motivational Deficits and Cognitive Test Performance in Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1058.	11.0	122
155	Glutamate-mediated excitotoxicity in schizophrenia: A review. <i>European Neuropsychopharmacology</i> , 2014, 24, 1591-1605.	0.7	115
156	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1007-1016.	1.2	24
157	Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 83-91.	4.8	15
158	Psychosis in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 485-499.	2.6	66
159	Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia. <i>Human Brain Mapping</i> , 2013, 34, 1035-1043.	3.6	38
160	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. <i>Psychopharmacology</i> , 2013, 228, 43-51.	3.1	15
161	Glutamate Levels in the Associative Striatum Before and After 4 Weeks of Antipsychotic Treatment in First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 1057.	11.0	175
162	The potential role of dopamine D3 receptor neurotransmission in cognition. <i>European Neuropsychopharmacology</i> , 2013, 23, 799-813.	0.7	153

#	ARTICLE	IF	CITATIONS
163	Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 178-182.	4.8	25
164	Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 471-475.	2.1	78
165	Reply to "Letter in reference to de la Fuente-Sandoval, C. et al. <i>Neuropsychopharmacology</i> 36, 1781-1791, 2011". <i>Neuropsychopharmacology</i> , 2012, 37, 1069-1069.	5.4	0
166	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. <i>Psychiatry Research</i> , 2012, 197, 1-6.	3.3	148
167	Neural response to experimental heat pain in stable patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2012, 46, 128-134.	3.1	16
168	Treatment resistant schizophrenia and response to antipsychotics: A review. <i>Schizophrenia Research</i> , 2011, 133, 54-62.	2.0	99
169	Dopamine D2 Receptor Occupancy and Clinical Effects. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 497-502.	1.4	117
170	Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 318-325.	1.4	77
171	Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2011, 36, 1781-1791.	5.4	214
172	Functional magnetic resonance imaging response to experimental pain in drug-free patients with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 99-104.	1.8	31
173	Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [¹⁸ F]setoperone PET study. <i>Social Neuroscience</i> , 2010, 5, 375-383.	1.3	24
174	Blockade of [¹¹ C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 273.	2.1	63
175	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.	12.3	97
176	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [¹¹ C](+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	5.4	109
177	Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT _{2A}) receptors in older, healthy adults. <i>BMC Medical Imaging</i> , 2009, 9, 12.	2.7	10
178	Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. <i>Schizophrenia Research</i> , 2009, 109, 130-133.	2.0	15
179	Brain region binding of the D2/3 agonist [¹¹ C](+)-PHNO and the D2/3 antagonist [¹¹ C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.	3.6	95
180	Cerebral blood flow changes associated with experimental pain stimulation in patients with major depression. <i>Journal of Affective Disorders</i> , 2008, 107, 161-168.	4.1	33

#	ARTICLE	IF	CITATIONS
181	Temporal Difference Modeling of the Blood-Oxygen Level Dependent Response During Aversive Conditioning in Humans: Effects of Dopaminergic Modulation. Biological Psychiatry, 2007, 62, 765-772.	1.3	138
182	Repetitive transcranial magnetic stimulation of dorsolateral prefrontal cortex increases tolerance to human experimental pain. Cognitive Brain Research, 2005, 25, 153-160.	3.0	129
183	Correlation between cerebral blood flow and items of the Hamilton Rating Scale for Depression in antidepressant-naïve patients. Journal of Affective Disorders, 2004, 80, 55-63.	4.1	42